Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer
Abstract Cetuximab is approved for the treatment of metastatic colorectal cancer (mCRC) with RAS wild-type. Nevertheless, the prognosis remains poor and the effectiveness of cetuximab is limited in KRAS mutant mCRC. Recently, emerging evidence has shown that ferroptosis, a newly discovered form of n...
Saved in:
Main Authors: | , , , , , , , |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Publishing Group
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/c2181e41f0cc462294e76d04f119e6f0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!